Recent advances in the diagnosis and management of cardiac amyloidosis

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The heart is commonly involved in various forms of amyloidosis and cardiomyopathy is a major cause of morbidity and mortality in these patients. Diagnosis of cardiac amyloidosis is often delayed due to nonspecific presenting symptoms and failure to recognize early signs of amyloid heart disease on routine cardiac imaging. Treatment of cardiac amyloidosis depends upon the type of amyloid protein. Systemic chemotherapy with or without stem cell transplantation is used to treat immunoglobulin-related amyloidosis and liver transplantation is used for familial transthyretin amyloidosis in select patients. Clinical trials with siRNA for the treatment of transthyretin amyloid cardiomyopathies and amyloid protein stabilizers are ongoing. Prognosis depends on the type of amyloid protein with poorer outcomes noted in immunoglobulin light-chain amyloidosis. Supportive care forms the cornerstone of management and advancements in cardiac imaging and proteomics are expected to positively impact our ability to diagnose, prognosticate and treat cardiac amyloidosis.

Original languageEnglish (US)
Pages (from-to)131-146
Number of pages16
JournalFuture Cardiology
Volume10
Issue number1
DOIs
StatePublished - Jan 2014

Fingerprint

Amyloidosis
Amyloidogenic Proteins
Cardiomyopathies
Amyloid
Familial Amyloidosis
Immunoglobulin Light Chains
Prealbumin
Stem Cell Transplantation
Liver Transplantation
Proteomics
Small Interfering RNA
Immunoglobulins
Heart Diseases
Clinical Trials
Morbidity
Drug Therapy
Mortality
Therapeutics

Keywords

  • amyloid cardiomyopathy
  • amyloid heart disease
  • cardiac amyloidosis

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Molecular Medicine

Cite this

Recent advances in the diagnosis and management of cardiac amyloidosis. / Sher, Taimur; Gertz, Morie.

In: Future Cardiology, Vol. 10, No. 1, 01.2014, p. 131-146.

Research output: Contribution to journalArticle

@article{59470e3a0ff14cfabf0394a3a8f090ee,
title = "Recent advances in the diagnosis and management of cardiac amyloidosis",
abstract = "The heart is commonly involved in various forms of amyloidosis and cardiomyopathy is a major cause of morbidity and mortality in these patients. Diagnosis of cardiac amyloidosis is often delayed due to nonspecific presenting symptoms and failure to recognize early signs of amyloid heart disease on routine cardiac imaging. Treatment of cardiac amyloidosis depends upon the type of amyloid protein. Systemic chemotherapy with or without stem cell transplantation is used to treat immunoglobulin-related amyloidosis and liver transplantation is used for familial transthyretin amyloidosis in select patients. Clinical trials with siRNA for the treatment of transthyretin amyloid cardiomyopathies and amyloid protein stabilizers are ongoing. Prognosis depends on the type of amyloid protein with poorer outcomes noted in immunoglobulin light-chain amyloidosis. Supportive care forms the cornerstone of management and advancements in cardiac imaging and proteomics are expected to positively impact our ability to diagnose, prognosticate and treat cardiac amyloidosis.",
keywords = "amyloid cardiomyopathy, amyloid heart disease, cardiac amyloidosis",
author = "Taimur Sher and Morie Gertz",
year = "2014",
month = "1",
doi = "10.2217/fca.13.85",
language = "English (US)",
volume = "10",
pages = "131--146",
journal = "Future Cardiology",
issn = "1479-6678",
publisher = "Future Medicine Ltd.",
number = "1",

}

TY - JOUR

T1 - Recent advances in the diagnosis and management of cardiac amyloidosis

AU - Sher, Taimur

AU - Gertz, Morie

PY - 2014/1

Y1 - 2014/1

N2 - The heart is commonly involved in various forms of amyloidosis and cardiomyopathy is a major cause of morbidity and mortality in these patients. Diagnosis of cardiac amyloidosis is often delayed due to nonspecific presenting symptoms and failure to recognize early signs of amyloid heart disease on routine cardiac imaging. Treatment of cardiac amyloidosis depends upon the type of amyloid protein. Systemic chemotherapy with or without stem cell transplantation is used to treat immunoglobulin-related amyloidosis and liver transplantation is used for familial transthyretin amyloidosis in select patients. Clinical trials with siRNA for the treatment of transthyretin amyloid cardiomyopathies and amyloid protein stabilizers are ongoing. Prognosis depends on the type of amyloid protein with poorer outcomes noted in immunoglobulin light-chain amyloidosis. Supportive care forms the cornerstone of management and advancements in cardiac imaging and proteomics are expected to positively impact our ability to diagnose, prognosticate and treat cardiac amyloidosis.

AB - The heart is commonly involved in various forms of amyloidosis and cardiomyopathy is a major cause of morbidity and mortality in these patients. Diagnosis of cardiac amyloidosis is often delayed due to nonspecific presenting symptoms and failure to recognize early signs of amyloid heart disease on routine cardiac imaging. Treatment of cardiac amyloidosis depends upon the type of amyloid protein. Systemic chemotherapy with or without stem cell transplantation is used to treat immunoglobulin-related amyloidosis and liver transplantation is used for familial transthyretin amyloidosis in select patients. Clinical trials with siRNA for the treatment of transthyretin amyloid cardiomyopathies and amyloid protein stabilizers are ongoing. Prognosis depends on the type of amyloid protein with poorer outcomes noted in immunoglobulin light-chain amyloidosis. Supportive care forms the cornerstone of management and advancements in cardiac imaging and proteomics are expected to positively impact our ability to diagnose, prognosticate and treat cardiac amyloidosis.

KW - amyloid cardiomyopathy

KW - amyloid heart disease

KW - cardiac amyloidosis

UR - http://www.scopus.com/inward/record.url?scp=84891092973&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891092973&partnerID=8YFLogxK

U2 - 10.2217/fca.13.85

DO - 10.2217/fca.13.85

M3 - Article

C2 - 24344669

AN - SCOPUS:84891092973

VL - 10

SP - 131

EP - 146

JO - Future Cardiology

JF - Future Cardiology

SN - 1479-6678

IS - 1

ER -